<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04575194</url>
  </required_header>
  <id_info>
    <org_study_id>Obesity drugs study</org_study_id>
    <nct_id>NCT04575194</nct_id>
  </id_info>
  <brief_title>Study of the Cardiometabolic Effects of Obesity Pharmacotherapy</brief_title>
  <official_title>Cardiovascular and Metabolic Effects of Drugs for the Treatment of Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Athens Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National and Kapodistrian University of Athens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to compare the efficacy of liraglutide vs.&#xD;
      naltrexone/bupropion on metabolic and cardiovascular risk markers, weight loss, as well as&#xD;
      the postprandial secretion of gastrointestinal hormones involved in hunger and satiety, after&#xD;
      a test meal. The study will include 40 patients, who will further be divided into two&#xD;
      treatment groups (20 patients on liraglutide vs. 20 patients on naltrexone/bupropion). The&#xD;
      patients will be examined at baseline, 3 and 6 months after the treatment initiation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective study of patients aged ≥18 years, who are overweight (BMI ≥ 27 kg / m2&#xD;
      in the presence of dyslipidemia or hypertension or obstructive sleep apnea or fatty&#xD;
      infiltration or prediabetes) or obese patients (BMI ≥ 30 kg / m2). Patients' data will be&#xD;
      collected before starting medication (time 0) and at 3 and 6 months under treatment in the&#xD;
      clinical practice of the selected drug, as described in the drug's package leaflet, along&#xD;
      with a simultaneous dietary intervention and exercise. Patient groups will be comparable in&#xD;
      age, gender and BMI.&#xD;
&#xD;
      The aim of the study is the comparison of the efficacy of liraglutide vs.&#xD;
      naltrexone/bupropion in metabolic and cardiovascular markers.&#xD;
&#xD;
      The following parameters will be measured:&#xD;
&#xD;
        -  Weight, height, waist and hip circumference&#xD;
&#xD;
        -  24-hour recording of blood pressure and heart rate&#xD;
&#xD;
        -  HbA1c, total cholesterol, LDL, HDL, urine albumin/creatinine ratio&#xD;
&#xD;
        -  Bioelectric impedance for determination of total and visceral fat and muscle mass&#xD;
           Indirect calorimetry for the determination of resting metabolic rate and total energy&#xD;
           expenditure&#xD;
&#xD;
        -  Determination of baroreflex sensitivity (BRS) and heart rate variability (HRV) to&#xD;
           investigate the function of the autonomic nervous system&#xD;
&#xD;
        -  Blood sample test meal at 0, 30, 60, 90, 120, 150 and 180 min to determine insulin&#xD;
           concentration and gastrointestinal hormones involved in hunger and satiety with modern&#xD;
           indirect calorimetry to determine postprandial thermogenic analog scales (VAS)&#xD;
&#xD;
        -  Neuropathy tests&#xD;
&#xD;
        -  Assessment of quality of life with the SF-36 questionnaire and assessment of the feeling&#xD;
           of hunger and satiety&#xD;
&#xD;
        -  Echocardiographic determination of the left systolic and telodiastolic diameter of the&#xD;
           left ventricle, cardiac fat and the Tei index at times 0 and 6 months with medication&#xD;
&#xD;
        -  Pericardial fat&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 8, 2020</start_date>
  <completion_date type="Anticipated">May 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in blood pressure</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Blood pressure as assessed by 24-hour recording (numerical scale)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight loss</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Percentage of weight lost will be measured by an electronic scale (numerical scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glycemic</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Measurement of HbA1c will be measured biochemically (numerical scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lipemic profile</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Total cholesterol, Triglycerides, LDL-C, HDL-C will be measured biochemically (numerical scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of visceral fat</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Measurement of visceral fat by bioimpedance analysis (numerical scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat mass</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Measurement of fat mass by bioimpedance analysis (numerical scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat free mass</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Measurement of fat free mass by bioimpedance analysis (numerical scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomic nervous system function</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Measurement of heart rate variability will be measured through Ewing score and Spectral analysis testing (numerical scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in meal induced thermogenesis</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Measurement through indirect calorimetry and assessment of changes in Resting Metabolic Rate (RMR) (numerical scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in gut hormones involved in appetite regulation</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Measurement in plasma before and after the intervention during a mixed meal test will be measured through ELISA kits (numerical scale)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Obesity</condition>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>Liraglutide 3 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be prescribed sc liraglutide 3 mg/day along with a dietary and physical activity intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone/bupropion 32/360 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be prescribed oral naltrexone/bupropion 32/360 mg/day along with a dietary and physical activity intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide 6 MG/ML [Saxenda]</intervention_name>
    <description>3 mg of sc liraglutide daily plus lifestyle intervention</description>
    <arm_group_label>Liraglutide 3 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone-Bupropion Combination</intervention_name>
    <description>32/360 mg of oral lnaltrexone-bupropion daily plus lifestyle intervention</description>
    <arm_group_label>Naltrexone/bupropion 32/360 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years with BMI ≥ 30 kg / m2 or BMI ≥ 27 kg / m2 in the presence of&#xD;
             dyslipidemia or hypertension or obstructive sleep apnea or fatty infiltration or&#xD;
             prediabetes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of any clinical contraindications for the administration of liraglutide or&#xD;
             bupropion / naltrexone&#xD;
&#xD;
          2. Bariatric surgery&#xD;
&#xD;
          3. Diabetes type 2&#xD;
&#xD;
          4. Active malignancy&#xD;
&#xD;
          5. Medication that affects weight (eg corticosteroids, phenothiazines)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandros Kokkinos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National and Kapodistrian University of Athens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandros Kokkinos, MD, PhD</last_name>
    <phone>+302132061248</phone>
    <email>rjd@otenet.gr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Georgia Argyrakopoulou, MD, PhD, MSc</last_name>
    <phone>+306972284033</phone>
    <email>gargyrakopoulou@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Department of Propaedeutic Internal Medicine</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandros Kokkinos, MD, PhD</last_name>
      <phone>2132061248</phone>
      <email>rjd@otenet.gr</email>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>October 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National and Kapodistrian University of Athens</investigator_affiliation>
    <investigator_full_name>Alexandros Kokkinos</investigator_full_name>
    <investigator_title>Associate Professor in Internal Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

